Lixin is the Chairman of Asia Regenerative Medicine Group and has extensive executive experience at industry and healthcare giants such as McKinsey & Co. (USA), SmithKline Beecham Pharmaceuticals (USA), and GSK Pharmaceutical (UK). With over 20 years of involvement in healthcare, medical devices, and investment, Lixin serves on the Board of many organ and device companies such as IVIVA Medical and Riton Dental Tech. Lixin holds an MBA degree from the Ivey Business School at Western University, Canada, and a Master’s Degree in Applied Science from the University of Toronto, Canada.

Nick Atwater is a Regenerative medicine expert with over 20 years of experience in biotechnology and academia. Nick held various leading research positions at organizations including the Harvard Stem Cell Institute and Quiver Biosciences before joining Rain Biotech Solutions. He received his MSc in Biotechnology and Bioinformatics from California State University, Channel Islands, and also completed a Masters in Business Management from Harvard University. After consulting for DM Healthcare investment group since 2018, Nick joined RBS as CEO in August of 2023.

Microfluidics and gene sequencing expert

Project lead on first commercial microfludic-based sequencing device

PhD, Zhejiang University

Postdoctoral fellow at HKU Advanced Biomedical Instrumentation Centre

Founder of VisionDrop AI, AI driven microfluidic based water testing device

Investor Relations Partner, Nextsequence

Microfluidics, Biosensors, and AI expert

PhD HKUST, Chemistry